Insider · CIK 0001857447
Brian McKelligon
Files at AKYA (Akoya Biosciences, Inc.). First filing -, latest -.
Brian McKelligon files SEC Form 4 as CEO, president and director at AKYA (Akoya Biosciences, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Brian McKelligon has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 14 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | JOther Common Stock | +393,338 | - | - | 813,464 | Jul 10, 2025 |
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | JOther Common Stock | +331,090 | - | - | 1,144,554 | Jul 10, 2025 |
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | FTax withholding Common Stock | -196,866 | - | - | 947,688 | Jul 10, 2025 |
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | JOther Common Stock | -947,688 | - | - | 0 | Jul 10, 2025 |
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | JOther Employee Stock Option (Right to Buy)derivative | -393,338 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | JOther Employee Stock Option (Right to Buy)derivative | -331,090 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | JOther Employee Stock Option (Right to Buy)derivative | -241,592 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | JOther Employee Stock Option (Right to Buy)derivative | -160,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | JOther Employee Stock Option (Right to Buy)derivative | -160,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Jul 8, 2025 | AKYA Akoya Biosciences, Inc. | JOther Employee Stock Option (Right to Buy)derivative | -175,000 | $0.00 | $0 | 0 | Jul 10, 2025 |
| Mar 23, 2025 | AKYA Akoya Biosciences, Inc. | FTax withholding Common Stock | -7,550 | $1.70 | $13k | 420,126 | Mar 25, 2025 |
| Mar 1, 2025 | AKYA Akoya Biosciences, Inc. | FTax withholding Common Stock | -7,550 | $1.63 | $12k | 435,933 | Mar 4, 2025 |
| Mar 1, 2025 | AKYA Akoya Biosciences, Inc. | FTax withholding Common Stock | -8,257 | $1.63 | $13k | 427,676 | Mar 4, 2025 |
| Nov 19, 2024 | AKYA Akoya Biosciences, Inc. | AGrant or award Common Stock | +218,750 | $0.00 | $0 | 443,483 | Nov 21, 2024 |
Questions about Brian McKelligon
Answered from the filings on this page, as of the latest one.
Is Brian McKelligon buying or selling?
Brian McKelligon has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Brian McKelligon's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Brian McKelligon has 0.
Where does Brian McKelligon file Form 4?
Brian McKelligon has filed Form 4 at AKYA (Akoya Biosciences, Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.